Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.
TypePrivate
HQMilton, GB
Founded2012
Websiteatopixtherapeutics.com
Atopix was founded in 2012 and is headquartered in Milton, GB
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Atopix

Mark Parry-Billings

Mark Parry-Billings

Director
Mick Hunter

Mick Hunter

Chief Scientific Officer and Director of Development
Roy Pettipher

Roy Pettipher

Director of Research
Show more

Atopix Office Locations

Atopix has an office in Milton
Milton, (HQ)
Milton Park Innovation Centre 99 Park Dr
Show all (1)
Report incorrect company information

Atopix Financials and Metrics

Summary Metrics

Founding Date

2012

Atopix total Funding

$5.1 m

Atopix latest funding size

$5.07 m

Time since last funding

3 years ago

Atopix investors

Atopix's latest funding round in July 2015 was reported to be $5.1 m. In total, Atopix has raised $5.1 m
Show all financial metrics

Atopix Revenue

Atopix's revenue was reported to be £453.37 k in FY, 2017
GBP

Revenue (FY, 2017)

453.4k

Net income (FY, 2017)

592.1k

EBITDA (FY, 2017)

591.5k

EBIT (FY, 2017)

587.7k

Cash (31-Dec-2017)

483.0
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

225.3k626.7k316.0k453.4k

Revenue growth, %

178%(50%)

Operating expense total

2.0m2.9m4.8m(134.3k)

EBITDA

(1.8m)(2.3m)(4.5m)(3.3m)591.5k
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.9m2.5m1.3m431.3k483.0

Accounts Receivable

260.080.0109.0

Current Assets

2.4m3.1m2.2m783.2k725.2k

PP&E

64.064.06.3k3.0k3.9k
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(2.1m)(2.5m)(4.7m)(3.4m)592.1k

Cash From Operating Activities

(1.8m)

Cash From Financing Activities

3.7m

Net Change in Cash

1.9m
GBPY, 2017

Financial Leverage

-0.3 x
Show all financial metrics
Report incorrect company information

Atopix Company Life and Culture

Report incorrect company information

Atopix Frequently Asked Questions

  • When was Atopix founded?

    Atopix was founded in 2012.

  • Who are Atopix key executives?

    Atopix's key executives are Mark Parry-Billings, Mick Hunter and Roy Pettipher.

  • What is Atopix revenue?

    Latest Atopix annual revenue is £453.4 k.

  • Who are Atopix competitors?

    Competitors of Atopix include Biothera, AKESOgen and NuCana.

  • Where is Atopix headquarters?

    Atopix headquarters is located at Milton Park Innovation Centre 99 Park Dr, Milton.

  • Where are Atopix offices?

    Atopix has an office in Milton.

  • How many offices does Atopix have?

    Atopix has 1 office.